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Abstract
Squamous cell carcinoma antigen (SCCA) belongs to the serine protease inhibitor (Serpin) family of proteins. Elevated
expression of SCCA has been used as a biomarker for aggressive squamous cell carcinoma (SCC) in cancers of the cervix,
lung, head and neck, and liver. However, SCCA expression in breast cancer has not been investigated. Immunohistochemical
analysis of SCCA expression was performed on tissue microarrays containing breast tumor tissues (n=1,360) and normal
breast epithelium (n=124). SCCA expression was scored on a tiered scale (0-3) independently by two evaluators blind to the
patient’s clinical status. SCCA expression was observed in Grade I (0.3%), Grade II (2.5%), and Grade III (9.4%) breast cancers
(p,0.0001). Comparing tissues categorized into the three non-metastatic TNM stages, I-III, SCCA positivity was seen in 2.4%
of Stage I cancers, 3.1% of Stage II cancers, and 8.6% of Stage III breast cancers (p=0.0005). No positive staining was
observed in normal/non-neoplastic breast tissue (0 out of 124). SCCA expression also correlated to estrogen receptor/
progesterone receptor (ER/PR) double-negative tumors (p=0.0009). Compared to SCCA-negative patients, SCCA-positive
patients had both a worse overall survival and recurrence-free survival (p,0.0001 and p,0.0001, respectively). This study
shows that SCCA is associated with both advanced stage and high grade human breast carcinoma, and suggests the
necessity to further explore the role of SCCA in breast cancer development and treatment.
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Introduction
Squamous cell carcinoma antigens (SCCA) are members of the
serpin family of endogenous serine proteinase inhibitors. The first
variant of SCCA, SCCA1, was originally identified in squamous
cell carcinoma (SCC) of the uterine cervix [1]. Further studies
found that SCCA1 and its isoform, SCCA2, are produced by two
tandemly arranged genes located on chromosome 18q21 [2].
SCCA1 and SCCA2 are approximately 98% and 92% homolo-
gous at their nucleotide and amino acid levels, respectively.
Although SCCA1 and SCCA2 inhibit different classes of
proteases, dictated by differences in amino acids located in the
reactive site loop (RSL), both isoforms are expressed in stratified
squamous epithelia and have been found to be produced in SCCs
[3,4]. High levels of SCCA are often associated with poorly
differentiated and advanced metastatic SCCs. In clinical practice,
immunohistochemistry on tissue biopsies and ELISA-based
detection of circulating SCCA (including both SCCA1 and
SCCA2) are currently used as valuable predictors of nodal
metastasis, response to treatment, and tumor recurrence in SCCs
of the uterine cervix, lung, head and neck, esophagus, and liver
[5,6].
Thus far, elevated levels of SCCA have been seen in cancers of
epithelial (cervix, lung, head and neck) and endodermal (liver)
origin. However, despite the epithelial origin of breast ductal and
lobular carcinomas, there have been no reports correlating SCCA
expression to breast cancer. Here, we sought to examine whether
SCCA is associated with human breast cancer.
Results
Validation of SCCA antibodies
First, we tested three commercially available antibodies that
have been previously described [7] for immunoblotting and
immunohistochemistry (IHC) analysis. According to the manu-
facturer’s instruction, one antibody is supposed to recognize both
SCCA1 and SCCA2 (Santa Cruz Biotechnology, Inc. Clone FL-
390), one to recognize specifically SCCA1 (Santa Cruz, Clone
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Clone 10C12). We characterized these three antibodies using
293T cells transfected with Flag-SCCA1 or Flag-SCCA2. While
Clone FL-390 recognized both SCCA1 and SCCA2, and Clone
10C12 specifically recognized SCCA2 as described by the
manufacturer, Clone 8H11 failed to recognize SCCA1 and
instead recognized SCCA2 (Fig. 1A). The specificity of the
antibodies was further examined by immunocytochemistry using
paraffin-embedded 293T cells expressing Flag-SCCA1 or Flag-
SCCA2. Similar to the immunoblotting analysis, Clone FL-390
recognized both SCCA1 and SCCA2, while Clone 10C12
recognized only SCCA2 (Fig. 1B). The 8H11 antibody, which
was described to specifically recognize SCCA1 (Santa Cruz
Biotechnology Product Information; [8]), failed to do so in our
hands. These results indicate that Clone FL-390 is a reliable and
more efficient antibody for recognizing both SCCA1 and SCCA2.
Indeed, when FL-390 was tested on paraffin-embedded normal
human tissues, it revealed SCCA expression in the ciliated pseudo-
stratified columnar epithelial of the bronchus, in suprabasal and
basal epidermal keratinocytes, and in the suprabasal keratinocytes
of the stratified squamous epithelial of the anal mucosa (Fig. 1C),
consistent with reports in literature describing SCCA expression
patterns [7]. Therefore, although efforts have been reported to
individually detect SCCA1 and SCCA2, as these two isoforms
have distinct biological functions [8,9], we choose to use Clone FL-
390 for the subsequent immunoblotting and IHC assays, because
1) Clone FL-390 has better efficiency for both immunoblotting
and IHC analysis; and 2) based on current clinical studies, an assay
recognizing both SCCA1 and SCCA2 is recommended for
optimal clinical sensitivity [10].
SCCA expression is elevated in breast cancer cell lines
and tissues
In searching for evidence that SCCA may be associated with
human breast cancer, we first compared SCCA expression levels
among a number of tumor cell lines including a non-neoplastic
breast epithelial cell line MCF10A, breast cancer lines (T47D,
MCF7, MDA-MB-468, SK-BR-3, Hs578T, and MDA-MB-231),
pancreatic cancer lines (CFPac-1, MIA PaCa-2, PANC-1),
osteosarcoma lines (U-2 OS and SAOS-2), and ovarian cancer
lines (OVCAR-4 and OVCAR-5). SCCA was detected at various
levels in 5 out of 6 of the breast cancer cell lines (Fig. 2A),
indicating that SCCA expression is elevated in certain types of
breast cancers. It remains to be determined why the bands on the
immunoblots appeared to migrate differently in these breast
cancer cell lines (Fig. 2A). Possible explanations include the
different isoforms of SCCA or the proteolytic cleavage of SCCA
[11]. Interestingly, the 5 positive cell lines (T47D, MCF7, MDA-
MB-468, SK-BR-3, and MDA-MB-231) were derived from
metastatic invasive ductal carcinomas [12,13], whereas the
Hs578T cell line was derived from a patient with primary
carcinosarcoma [14]. Taken together, these results indicate that
expression of SCCA is elevated in certain breast cancers and may
correlate with invasive ductal carcinoma.
We next examined the expression of SCCA in human breast
cancer tissues. A breast carcinoma progression tissue microarray
(TMA) was obtained from the Cooperative Human Tissue
Network (CHTN) at the University of Virginia. This TMA
contained 7 cases of non-neoplastic breast epithelium from healthy
subjects, 7 cases of non-neoplastic breast epithelium from subjects
with breast cancer, and 42 cases ranging from low grade ductal
carcinoma in situ (DCIS) to metastatic breast carcinoma. IHC was
performed with Clone FL-390. Immunohistochemical staining was
semi-quantitatively scored on a tiered scale (0-3) as a percentage of
positive tumor cells (Fig. 2C). The expression levels were recorded
as percent of tumor cells with SCCA expression 0 (no positive
staining), 1 (positive staining in less than 10% of cells), 2 (positive
staining in 10-50% of cells), and 3 (positive staining in over 50%
cells). Tumor tissues with a score higher than 1 were counted
positive for SCCA expression. Elevated expression of SCCA was
detected in 4 high grade and one low grade tumors, and was not
present in normal breast tissue (Fig. 2B). These results indicate that
SCCA expression is elevated in certain breast cancers.
SCCA expression in breast carcinomas correlates to both
grade and stage
To further investigate the involvement of SCCA in breast
cancer, we obtained two large scale TMA case sets from the NCI
Cancer Diagnosis Program (CDP). One is the 2nd generation
breast cancer progression TMA, and the other is the CDP 2008
breast cancer prognostic TMA that contains three non-metastatic
TNM stages I-III as defined by AJCC Manual for Staging of
Cancer [15]. SCCA expression was detected by IHC using Clone
FL-390. In the NCI CDP progression TMA, IHC analysis
revealed that all of the normal breast tissue specimens were
negative for SCCA expression. When compared with the grading
information provided for the 291 cases, SCCA was found in only
Grade II (n=5) and Grade III (n=8) specimens (p=0.016)
(Table 1). These results indicate that elevated SCCA expression is
associated with breast carcinomas but not normal breast
epithelium, and this expression correlates with the grade of the
invasive cancer.
In the prognostic TMA case sets, SCCA expression was also
detected in primarily Grade II and Grade III tissue specimens,
only 1 Grade I sample screened positive (p,0.0001) (Table 2).
Strikingly, 68.5% of the positive specimens corresponded with
Grade III breast carcinoma even though Grade III specimens
were underrepresented in these TMA case sets (only 28.9% of the
total breast carcinoma tissue samples). Cumulatively, among the
CDP progression (Table 1) and the prognostic (Table 2) TMAs, all
124 non-neoplastic specimens were found to be SCCA negative,
whereas 1 of the 330 (0.3%) Grade I cases, 16 of the 638 (2.5%)
Grade II cases and 37 of the 392 (9.4%) Grade III cases were
SCCA-positive (p,0.0001) (Table 3). Importantly, SCCA posi-
tivity also correlated with stage of the disease, as 8.6% of Stage III
tissue samples tested positive for SCCA expression, whereas only
2.4% and 3.1% of Stage I and II samples, respectively, showed
SCCA expression (p=0.0005) (Table 4). In addition, our study
encompassed 1,138 breast cancer samples with ductal/lobular
classification. While 40 of the 1,029 ductal carcinoma specimens
were SCCA-positive, only 1 SCCA-positive case was found in the
109 lobular carcinoma specimens.
Moreover, while no statistical difference was detected for the
mean age of diagnosis (p=0.38), the mean size of tumors was 2.41
cm for SCCA-negative versus 3.58 cm for SCCA-positive tumors
(p,0.0001). The progression TMA also came with information for
Figure 1. Validation of SCCA antibodies. 293T cells were transfected with either vector alone, Flag-SCCA1, or Flag-SCCA2 plasmids. (A) Cells
were subjected to immunoblot analysis using three SCCA antibodies: FL-390 for SCCA1/2, 8H11 for SCCA1, and 10C12 for SCCA2, as well as Flag
antibody and b-tubulin antibody. (B) Cells were fixed and embedded in paraffin. IHC was performed with FL-390 and 10C12 antibodies. (C) IHC was
performed on normal human tissue using the antibody Clone FL-390. Scale bars =50 mm.
doi:10.1371/journal.pone.0019096.g001
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19096Figure 2. Elevated SCCA expression is found in human breast cancer cell lines and human breast cancer carcinomas, but not in
normal breast epithelium. (A) A panel of human cancer cells was probed for SCCA expression by immunoblotting. Five out of the six breast cancer
cell lines (denoted with an asterisk) were positive for SCCA expression. (B) IHC analysis was performed on an array of breast carcinomas and normal
breast tissue obtained from CHTN, using antibody FL-390. Representative images of normal breast tissue and sections with Grade III invasive ductal
carcinoma are shown. (C) IHC staining was performed on the NCI CDP breast cancer progression and the prognostic TMAs using antibody FL-390.
SCCA staining was scored on a tiered-scale (0–3). A representative panel is shown. Scale bars =50 mm.
doi:10.1371/journal.pone.0019096.g002
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receptor (PR), but not Her2/neu status. Out of the 13 SCCA
positive breast carcinoma specimens, 9 cases (69%) were classified
as double negative (DN) for the expression of both ER and PR,
whereas only 24% of the SCCA-negative tumor specimens were
DN (p=0.0009). This is consistent with the notion that tumors
negative for both hormone receptors are more likely to be Grade
III and to have a larger mean tumor size [16]. Taken together, the
IHC results obtained from both the progression and prognostic
TMAs indicate that SCCA expression correlates to high grade and
high stage breast carcinomas.
SCCA correlates with decreased chance of overall survival
and recurrence-free survival
Following the proposal by Hudis et al [17], survival analyses
were carried out to compare both overall survival (OS) and
recurrence-free survival (RFS) using the information included with
the prognostic TMAs. SCCA positivity correlated with decreased
OS and RFS (Fig. 3A–B) (OS; hazard ratio (HR), 2.75; 95% CI,
1.62–4.68; Log-rank p=0.0002) (RFS: HR, 4.64; 95% CI, 2.26–
9.55; Log-rank p,0.0001). Furthermore, comparing only Grade
II and III breast cancers, patients with SCCA expression had a
decreased OS (HR, 2.08; 95% CI, 1.26–3.44; Log-rank=0.004).
The median OS was 155.0 months for SCCA-negative patients,
with a 5-year survival rate of 79.1%, whereas the median OS was
88.0 months, with a 5-year survival rate of 54.2% for patients
positive for SCCA (Fig. 3C). SCCA expression also correlated to a
worse RFS (HR, 3.08; 95% CI, 1.59–5.98; Log-rank p=0.0009).
Grade II and III SCCA-negative patients had a 5-year RFS of
74.4%, while SCCA-positive patients had a 5-year RFS of 42.2%
and a median time to recurrence of 52 months (Fig. 3D). These
results further support that SCCA expression correlates with high
grade breast cancer with poorer outcome.
Discussion
SCCA was originally identified as a serological marker in
cervical carcinoma [1]. Studies have shown that the SCCA levels
in the serum of cervical squamous cell carcinoma patients
correlates with the severity of the cancer [18]. SCCA levels have
also been shown to coincide to a degree with tumor infiltration and
frequency of lymph node metastasis in both cervical and
esophageal squamous cell carcinomas [5,19,20]. Here, our study
shows for the first time that elevated expression of SCCA is
associated with both high grade and advanced stage human breast
carcinomas. An accurate portrayal of the entire tumor may not be
represented in our study due to the nature of TMAs with regard to
the small tissue specimen size. Therefore we speculate that the
percentage of breast cancers with SCCA positivity may have been
under estimated in our study. Whole section biopsy samples will
help to more accurately assess the association of SCCA with breast
cancer. Similar reason may explain why an earlier study using
laser microdissection and microarray analysis did not indicate any
difference in SCCA expression between normal breast tissue,
ductal carcinomas, and lobular carcinomas, as only 5 invasive
ductal carcinomas and 5 invasive lobular carcinomas were
examined [21], and according to our study, SCCA positive
tumors represented only about 4% of breast cancer specimens.
In addition to the correlation between SCCA expression and
high grade and advanced stage breast carcinoma, we find that
those with SCCA-positive tumors have a worse clinical outcome,
including decreased OS and RFS. Our results are consistent with
other studies that have shown high levels of SCCA correlate to
disease recurrence [22]. Additionally, SCCA serum levels have
been regarded as a valuable marker of patient response to both
radiation and chemotherapy [18,23]. While our study links SCCA
tissue expression levels with disease state, overall survival and
recurrence, it hints at the possibility of utilizing SCCA serum levels
in breast cancer patients to determine clinical outcome and
response to therapy.
A number of reports have shown that breast SCC is an
aggressive disease behaving like poorly differentiated breast
adenocarcinoma [24,25]. Our finding that SCCA positivity is
associated with high grade breast carcinoma is consistent with this
notion. In addition, the features of the SCCA-positive cases we
identified in this study are very similar to those obtained from a
study carried out at M.D. Anderson Cancer Center, where 33
breast SCC patients identified from 1985–2001 were analyzed and
Table 1. SCCA expression correlates to high grade breast
cancer in the CDP progression TMA.
Case Set 3 Case Set 5 Case Set 7 Total
Normal tissue(SCCA
Positive)
23(0) 23(0) 23(0) 69(0)
Grade 1(SCCA Positive) 18(0) 9(0) 9(0) 36(0)
Grade 2(SCCA Positive) 34(2) 34(2) 36(1) 104(5)
Grade 3(SCCA Positive) 21(2) 33(3) 28(3) 82(8)
p=0.016
The three CDP progression TMA case sets (designated as Case Sets 3, 5, and 7
by CDP) were probed for SCCA expression and scored. The grading information
was provided by CDP in 291 accountable samples.
doi:10.1371/journal.pone.0019096.t001
Table 2. SCCA expression correlates to high grade breast carcinoma in the CDP prognostic TMA.
Case Sets 9–13 (Stage I) Case Sets 14–17 (Stage II) Case Sets 18–19 (Stage III) Total
Normal tissue(SCCA Positive) 25(0) 20(0) 10(0) 55(0)
Grade 1(SCCA Positive) 197(0) 73(0) 24(1) 294(1)
Grade 2(SCCA Positive) 268(4) 175(1) 91(6) 534(11)
Grade 3(SCCA Positive) 108(10) 143(11) 59(8) 310(29)
p,0.0001
The Stage I (Case Sets 9–13), Stage II (Case Sets 14–17), and Stage III (Case Sets 18–19) prognostic TMAs were obtained from CDP, containing 598, 411, and 184 tissue
specimens, respectively. IHC was performed against SCCA. The tissue was scored and the SCCA-positive cases are shown in parentheses against the number of cases in
each grade. Note that all of the normal tissue were SCCA-negative, whereas 1 out of 294 Grade I, 11 out of the 534 Grade II, and 29 out of 310 Grade III cases were SCCA-
positive.
doi:10.1371/journal.pone.0019096.t002
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expression may be indicative of breast SCC and has the potential
to be a valuable marker of breast SCC, as well as predicting
disease severity and response to treatment as has been demon-
strated in other SCCs.
Despite its clear clinical relevance, the biological function of
SCCA remains unclear. In some cancers, increased expression of
Serpins is likely to protect tumor cells by guarding against
lysosomal damage, release of toxic proteases such as cathepsins,
and subsequent cell death. On the other hand, elevated SCCA
may compromise the cell’s ability to degrade misfolded proteins,
and render tumor cells more vulnerable to treatment that causes
proteotoxicity. Consistent with the correlation between SCCA1
expression and high grade breast carcinoma, we have found that
ectopically expressed SCCA1 can induce de-differentiation of
MCF10A non-neoplastic breast cell line and promote transforma-
tion both in cell culture and in vivo (Sheshadri et al, unpublished
data). It is also interesting to note that while we detected elevated
SCCA expression in about 4% breast cancer specimens, 5 out of
the 6 breast cancer cell lines were positive for SCCA expression
(Fig. 2A). This suggests that SCCA-expressing cells may better
adapt to cell culture hence have a survival advantage under
stressed conditions. Hence, identifying SCCA in breast cancer
may provide a novel diagnostic approach that will help to
understand the initiation and advancement of breast cancer and
provide new therapeutic options.
Materials and Methods
Cell lines, culture, and transfection
T47D, MCF7, MDA-MB-468, SK-BR-3, MDA-MB-231,
MCF10A, CFPac-1, MIA PaCa-2, SAOS-2, U-2 OS, PANC-1,
and 293T cell lines were purchased from ATTC. Hs578T,
OVCAR-4, and OVCAR-5 were purchased from the Division of
Cancer Treatment and Diagnosis at National Cancer Institute. All
cells were cultured according to ATCC or NCI recommendations
supplemented with 100 units/ml penicillin and 100 mg/ml
streptomycin (Invitrogen). 293T cells were transfected by Lipo-
fectamine 2000 (Invitrogen).
Plasmids
Human SCCA1 was cloned by RT-PCR from total RNA of
MDA-MB-468 cells. Human SCCA2 was cloned by RT-PCR
from total RNA of MCF 10A cells. Primers used for cloning of
both SCCA1 and SCCA2: Forward primer, contains BamHI
restriction site and Flag tag: 59-CGGGATCCATGGACTA-
CAAGGACGACGATGACAAGACCATGAATTCACTCAGT-
GAAGCC-39. Reverse primer: contains XhoI restriction site: 59-
CCCTCGAGCATCTACGGG GATGAGAATCTGCCA-39.
RT-PCR products were ligated into the pCR2.1-TOPO vector
(Invitrogen) and verified through sequencing (Stony Brook
University DNA Sequencing Facility). Sequences were verified
against reported sequences at NCBI GenBank. Both SCCA1 and
SCCA2 were then subcloned into the LPC retroviral expression
vector.
Immunoblot analysis
Cell lysates were prepared in RIPA buffer (1% Sodium
Deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris
pH 8.0, 0.14 M NaCl). Protein expression was examined by
western blotting using SCCA1/2 (Santa Cruz, FL-390), SCCA1
(Santa Cruz, 8H11), SCCA2 (Santa Cruz, 10C12), FLAG (M2,
Sigma), and b-tubulin (Sigma). All primary antibodies were
incubated overnight at 4uC. Horseradish peroxidase-conjugated
goat anti-rabbit (Rockland) or goat anti-mouse (Rockland)
antibodies were used as secondary antibodies. Western blots were
developed using an ECL detection kit (Thermo Scientific).
Tissue microarrays
The tissue microarrays (TMAs) used in this study were obtained
from both the Cooperative Human Tissue Network (CHTN) at
the University of Virginia and the National Cancer Institute (NCI)
Cancer Diagnosis Program (CDP). The TMA obtained from the
CHTN contained 7 cases of non-neoplastic breast tissue from
healthy subjects, 7 cases of non-neoplastic breast tissue from
subjects with breast cancer, and 42 cases ranging from low grade
DCIS to metastatic breast carcinoma. The progression TMA
obtained from the CDP (Sets 3, 5, and 7) were designed by NCI
statisticians to provide high statistical power and are suitable for
use in the investigation of differences in the prevalence of potential
markers in invasive breast cancer. Each TMA consists of 288 cores
(0.6 mm) taken from paraffin-embedded specimens that represent
a total of 252 breast cancer and normal breast tissue specimens
plus 36 controls. The prognostic TMA obtained from the CDP
(Stage I, Sets 9–13; Stage II, Sets 14–17; Stage III, Sets 18–19) are
designed to examine potential prognostic markers in non-
metastatic breast cancer. Each TMA consists of between 100–
Table 3. SCCA expression correlates to high grade breast
carcinomas.
# SCCA Positive/Total Breast
Carcinoma Specimen
Normal/Non-Neoplastic 0/124
Grade I 1/330(0.3%)
Grade II 16/638 (2.5%)
Grade III 37/392 (9.4%)
p,0.0001
The cumulative results of the SCCA positivity against the breast carcinoma
grading from the CDP progression and prognostic TMAs are shown. SCCA is
negative in the 124 normal or non-neoplastic cases of breast tissue. SCCA is
positive in 1 of the 330 (0.3%) Grade I cases, 16 of the 638 (2.5%) Grade II cases,
and in 37 of the 392 (9.4%) Grade III cases.
doi:10.1371/journal.pone.0019096.t003
Table 4. SCCA expression correlates to advanced stage
breast carcinomas.
# SCCA Positive/Total Breast
Carcinoma Specimen
Normal/Non-Neoplastic 0/55
Stage I 14/573 (2.4%)
Stage II 12/391 (3.1%)
Stage III 15/174 (8.6%)
p=0.0005
The Stage I, Stage II, and Stage III prognostic TMAs were obtained from CDP.
IHC was against SCCA. The tissue was scored and the SCCA-positive cases are
shown in parentheses against the number of cases for each stage. Note that all
of the normal tissue were SCCA-negative, whereas 14 out of 573 (2.4%) Stage I,
12 out of the 391 (3.1%) Stage II, and 15 out of 174 (8.6%) Stage III cases were
SCCA-positive.
doi:10.1371/journal.pone.0019096.t004
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specimens plus 5–20 control cores.
Immunohistochemistry
Paraffin-embedded TMA arrays were deparaffinized and
rehydrated with graded ethanol. Endogenous peroxidase was
blocked using 3% hydrogen peroxide. Antigen retrieval was
accomplished using 10 mM citrate buffer (pH 6.0). The sections
were blocked with 5% goat serum for one hour at room
temperature. SCCA primary antibody (FL-390, 1:200; 10C12,
1:50) was diluted in the blocking solution. Slides were incubated
with the primary antibody overnight at 4uC. Slides were then
washed and incubated with the appropriate biotinylated secondary
antibody (1:1,000) for one hour at room temperature. Following a
wash series, tissue was incubated with avidin/biotinylated HRP
(ABC Elite kit from Vector Labs) according to manufacturer’s
instructions. Slides were submerged in diaminobenzidine (DAB)/
H2O2 substrate solution until the desired staining intensity was
obtained and slides were counterstained with hematoxylin. Slides
were observed and photographs taken using an Olympus BX41
microscope.
TMA analysis
Damaged core spots and those that were entirely adipose tissue
were eliminated from scoring. The sections were scored indepen-
dently by two evaluators blinded to the clinical status of the
patients. The results were classified as percent of tumor cells with
SCCA expression: 0, no expression; 1, ,10%; 2, 10–50%; 3,
.50%. Clinical data was then used to correlate SCCA expression
with various clinicopathological variables.
Statistical analysis
Two sample t-tests were used to compare continuous clinical
features, such as age and size of invasive tumor between SCCA-
negative and positive samples; Chi-squared tests and Fischer’s
exact tests, when applicable, were used to assess statistical
significance of various categorical clinical features between
SCCA-negative and SCCA-positive samples. Kaplan-Meier
Figure 3. SCCA expression correlates to a decreased overall survival and recurrence-free survival. IHC was performed using the SCCA
antibody FL-390 on the CDP prognostic TMAs. Kaplan-Meier survival curves for all patients (A–B) and only Grade II and Grade III patients (C–D) with
SCCA-positive and negative tumors were compared for overall survival (A&C) and recurrence-free survival (B&D).
doi:10.1371/journal.pone.0019096.g003
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were constructed for SCCA-negative and positive patients and
compared using the Log-rank (Mantel-Cox) test. Hazard ratios
and their 95% confidence intervals were derived, together with
median survival times and 5-year survival rates. Statistical analyses
were performed with GraphPad Prism (Graphpad Software Inc).
Two-sided P values ,0.05 were considered statistically significant.
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